Bone Marrow Transplantation

Papers
(The H4-Index of Bone Marrow Transplantation is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
When is a chimaera not a chimaera?283
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China94
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)74
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards71
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study66
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)63
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen62
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease60
Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes56
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency54
Low Incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin51
Health-related quality of life in pediatric patients with β-thalassemia major after hematopoietic stem cell transplantation48
Patient-generated strategies for strengthening adherence to multiple medication regimens after allogeneic stem cell transplantation: a qualitative study47
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma43
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study41
Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic ce38
The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease36
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the 34
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey34
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia34
Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peri33
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status32
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany31
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma31
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma28
Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy27
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma27
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients27
0.28033304214478